Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...
Texas Tech leaders once again vented about the Sorsby ruling and backlash to it in an oddball 20-plus-minute video on Friday. The more they talk, the worse it seems to get. Will Texas Tech face ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results